Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, You-cai, Liao, Xing-hui, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Zhong, Li-hua, Du, Kai-qi, Chen, Yan-ping, Chen, Gang, Fang, Mei-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499929/
https://www.ncbi.nlm.nih.gov/pubmed/28721068
http://dx.doi.org/10.2147/OTT.S139718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499929/
https://www.ncbi.nlm.nih.gov/pubmed/28721068
http://dx.doi.org/10.2147/OTT.S139718

Ejemplares similares